"…I know how my active PsA symptoms felt before and I know how much of my life I missed out on because of that. And, honestly, I can tell you that my worst day now is my best day then."
- Suzana, real TREMFYA® patient
For US Healthcare Professionals
I am a
Rheumatology Specialist
For US Healthcare Professionals
Full Prescribing Information
FOR ADULTS WITH ACTIVE PSORIATIC ARTHRITIS (PsA)
Prescribed* IL-23i in active PsA by rheumatologists
Prescribed* IL-23i in active PsA
by rheumatologists
*“#1 prescribed” refers to year-to-date TREMFYA® active PsA market share vs IL-23 inhibitors as of May 2024.
Source: IQVIA Weekly LAAD as of 05/31/24 X Free goods; Total PsA EqU share for Rheumatologists.
Take confidence in TREMFYA®, the #1 prescribed* IL-23i in active PsA by rheumatologists
Provides Durable
Improvement Across Domains
TREMFYA® provides the opportunity for durable improvement across joint and multiple key domains of active PsA and 90% patient retention at 2 years.2-5†‡§||
¶The same patients may not have responded at each time point.
Open-label active treatment NRI post hoc analysis at Week 100.
No conclusions regarding efficacy or safety can be drawn from retention data.
Open-label active treatment NRI post hoc analysis at Week 100. No conclusions regarding efficacy or safety can be drawn from retention data.
Open-label active treatment NRI post hoc analysis at Week 100.
No conclusions regarding efficacy or safety can be drawn from retention data.
Safety Profile in
Psoriatic Disease
TREMFYA® has a proven safety profile across psoriatic disease with 5 years of data in moderate to severe plaque psoriasis (PsO) and 2 years of data in
active PsA.1,2
A Differentiated
Mechanism
Selective IL-23 inhibitors like TREMFYA® block IL-23 and regulate IL-17A/F and IL-22 cytokines.1¶
TREMFYA® is the only# selective, dual-acting IL-23 inhibitor designed also to neutralize inflammation at its cellular source by binding to CD64.6¶**
¶The clinical significance is unknown.1,6
#Based on approved IL-23 inhibitors for active PsA as of April 2024.
**Findings are limited to in vitro studies.
Access options for all patients, and dedicated patient support
CD=cluster of differentiation; IL=interleukin;
NRI=nonresponder imputation method.
*“#1 prescribed” refers to year-to-date TREMFYA® active PsA market share vs IL-23 inhibitors as of May 2024. Source: IQVIA Weekly LAAD as of 05/31/24 X Free goods; Total PsA EqU share for Rheumatologists.
†The primary endpoint, ACR20 at Week 24, was met in the TREMFYA® arms in 2 clinical trials.
‡Year 2 represents Week 100 in DISCOVER 2.
§After Week 24, patients and doctors knew that all patients were on TREMFYA® (open label with a blinded dosing interval), which may have affected the results.
Access options for all patients, regardless of insurance coverage
92%* nationally preferred† first-line commercial coverage
No step edit required‡
ONCE A PRESCRIBING DECISION HAS BEEN MADE
*These percentages may not represent 100% of formulary lives due to data limitations.
†“Preferred” means TREMFYA® can be accessed first-line (ie, step therapy is not required) and its formulary status is better than or equivalent to other products in the class.
‡Requiring no step edits indicates a drug will be given first-line biologic access and will not require stepping through other biologic therapies.
References: 1. TREMFYA® (guselkumab) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 2. Data on file. Janssen Biotech, Inc. 3. Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naïve patients with active psoriatic arthritis (DISCOVER 2): a double-blind, randomized, placebo-controlled phase 3 trial. Lancet. 2020; 395(10230): 1126-1136. 4. McInnes IB, Rahman P, Gottlieb AB, et al. Long-term efficacy and safety of guselkumab, a monoclonal antibody specific to the p19 subunit of interleukin-23, through two years: results from a phase III, randomized, double-blind, placebo-controlled study conducted in biologic-naïve patients with active psoriatic arthritis. Arthritis Rheumatol. 2022;74(3):475-485. 5. McInnes IB, Rahman P, Gottlieb AB, et al. Efficacy and safety of guselkumab, an interleukin-23p19-specific monoclonal antibody, through one year in biologic-naïve patients with psoriatic arthritis. Arthritis Rheumatol. 2021;73(4):604-616. 6. Krueger J, Eyerich K, Greving C, et al. Poster #LB989. Differentiation of therapeutic antibodies targeting IL-23. Presented at the 2022 Society for Investigative Dermatology.
